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Intensive carePurpose: To survey healthcare workers (HCW) on availability and use of personal protective equipment (PPE)
caring for COVID-19 patients in the intensive care unit (ICU).
Materials and method: A web-based survey distributed worldwide in April 2020.
Results:We received 2711 responses from 1797 (67%) physicians, 744 (27%) nurses, and 170 (6%) Allied HCW.
For routine care, most (1557, 58%) reportedly used FFP2/N95 masks, waterproof long sleeve gowns (1623;
67%), and face shields/visors (1574; 62%). Powered Air-Purifying Respiratorswere used routinely and for intuba-
tion only by 184 (7%) and 254 (13%) respondents, respectively. Surgical maskswere used for routine care by 289
(15%) and 47 (2%) for intubations. At least one piece of standard PPE was unavailable for 1402 (52%), and 817
(30%) reported reusing single-use PPE. PPE was worn for a median of 4 h (IQR 2, 5). Adverse effects of PPE
were associated with longer shift durations and included heat (1266, 51%), thirst (1174, 47%), pressure areas
(1088, 44%), headaches (696, 28%), Inability to use the bathroom (661, 27%) and extreme exhaustion (492, 20%).e Hospital, Anzac Avenue, Redcliffe, QLD 4020, Australia.
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The SARS-CoV-2 virus and the disease it causes (Coronavirus Disease
2019; COVID-19) has created a global public health emergency follow-
ing its first appearance in December 2019 [1]. As of early june 2020
there had been more than 6.4 million confirmed cases and 385,000
deaths reported worldwide [2].
This highly contagious virus poses a significant but largely prevent-
able risk to healthcare workers (HCW) [3]. In some areas, HCW have
comprised up to 11% of all confirmed COVID-19 caseswith an increasing
number of occupationally attributed deaths being reported [4,5]. Use of
personal protective equipment (PPE) canmarkedly reduce the infection
risk associated with caring for COVID-19 patients [6,7]. While there is
little evidence to which PPE offers the best protection, training in don-
ning and doffing, simulation and face to face instructions are likely ben-
eficial [8]. As a result of adequacy of instruction, availability of fit-
testing, and supply limitations [9], HCW may not be utilizing PPE as
per recommended guidelines [6,10,11].
Reports of PPE scarcity and unavailability are emerging worldwide.
HCWs report on social media and the general press resorting to reusing
PPE or using household and self-made items in place of PPE. While lim-
ited evidence exists on the effectiveness of these practices, it has some-
times been done on the advice of their employers or health
organisations [12,13]. Pictures of HCWs' faces bruised by wearing
masks for extended periods have been used to illustrate the extreme
work conditions when caring for such patients. While pain, heat stress
and fluid loss with using Powered Air-Purifying Respirators (PAPR)
were predicted by experimental data [14], there are no real-life reports
of this issue when using PPE that is available to HCWs.
The objective of this studywas to describe the current reported prac-
tices, availability, training, confidence in the use and adverse effects due
to extended use of PPE by HCWs from around the world caring for
COVID-19 patients who require ICU management.
2. Methods
A web-based survey was conducted in order to elicit HCW reports
surrounding PPE related to the COVID-19 pandemic. Participation was
voluntary and anonymous. This study was approved and granted a
waiver of signed individual informed consent by the Royal Brisbane
and Women's Hospital Human Research Ethics Committee (LNR/2020/
QRBW/63041), Brisbane, Australia.
2.1. Survey instrument
The survey target population was all HCW of any discipline or train-
ing background or levelwho are directly involved in themanagement of
COVID-19 patients in a critical care setting. A 2-part study-specific sur-
vey was designed (see electronic supplement). In the first part, ques-
tions surrounding basic demographic, training experience, and
institutional work characteristics were elicited. No specific identifying
data (i.e. name, date of birth)was requested The second part comprised
of a series of questions regarding the usual practices and availability of
PPE, alongwith perceptions of its adequacy in terms of supply and train-
ing in the workplace as well as adverse effects of wearing PPE on the
HCW.
Questions were developed and the survey pre-tested for ease of ad-
ministration, flow, and content by management committee members
and by experienced clinician volunteers. Following iterative revisions,the final survey was developed. An English language version was pre-
pared then translated in the French, Spanish and Italian languages.
The survey started with a binary question: if the respondent de-
clared directly caring for COVID-19patients in the ICU setting the survey
was continued and the response categorized as valid. In the opposite
case the survey was terminated, and the response categorized as
invalid.
2.2. Survey administration
The final survey was prepared using the Surveymonkey® online
platform (SVMK Inc., San Mateo, USA) and posted at https://www.
surveymonkey.com/r/PPE-SAFE. The survey was planned to be open
for 2 weeks starting March 30. Only the English language version was
initially availablewith the others implemented as of April 7, 2020. Dura-
tion of the survey was subsequently extended and we report data col-
lected between March 30 and April 20, 2020.
Subjects were invited to participate through several venues includ-
ing email invitations usingmailing lists of the European Society of Inten-
sive Care Medicine, Australia and New Zealand Intensive Care Society,
Australian College of Critical Care Nurses, and the European Society of
Clinical Microbiology and Infectious Diseases. In addition, ad hoc emails
and advertisements weremade via personal networks and social media
accounts of management committee members.
2.3. Data management and analysis
Survey results were exported to and analysed using Stata 15.1 (Stata
Corp, College Station, USA). Means with standard deviations (SD) and
medianswith interquartile ranges (IQR)were used to describe normally
and non-normally distributed continuous variables, respectively. Differ-
ences in grouped means and medians were tested using the t-test and
Wilcoxon rank-sum test, respectively. Categorical data were compared
using the Chi-square or Fisher Exact Tests. A p-value less than 0.05
was deemed to represent significance for all comparisons. We per-
formed univariate logistic regression to test the effect of PPE-clad shift
duration, modelled as a continuous variable, on adverse effects. We
used a separate univariatemodel for each adverse effect, and for any ad-
verse effect.
3. Results
3.1. Description of the respondents
Valid responses were received from 2711 of 4879 (56%) individuals
who accessed the survey. Of which 1797 (67%) were physicians, 744
(27%) were nurses, and 170 (6%) were allied HCW (Table 1 and figure
e-sup 1). Themedian agewas 41 (IQR, 34–49), 1254 (46%)were female.
As detailed in the electronic supplement, respondents worked in 90 dif-
ferent countries, mostly from Europe (1666; 61%) followed by Asia
(437; 16%), and North America (224; 8%). Most (1585; 58%) respon-
dents worked in a COVID-19 dedicated ICU, including 281 (10%) in an-
other area re-purposed as a COVID-19 ICU. One third (924; 34%) of
subjects reported working in an ICU that contained patients with and
without COVID-19, and 201 (7%) worked in other areas. As shown in
Table 1, several characteristics were different among those working in
COVID-19 dedicated or repurposed ICUs as compared to mixed or
other ICUs.
Table 1
Comparison of demographic and workplace attributes among respondents working in
COVID-19 dedicated or repurposed ICUs as compared tomixed or other critical care areas.
Factor Total Mixed ICU,
COVID-19
ICU or other
COVID-19
dedicated or
re-purposed ICU
n = 2711 n = 1126 n = 1585
Age 41 (34–49) 42 (35–50) 41 (34–48)
Female gender 1254 (46%) 481 (43%) 773 (49%)
ICU experience (Years) 10 (4–18) 10 (5–20) 10 (4–17)
PPE shift duration (hours) 4 (2–6) 4 (2–6) 4 (2–6)
Position
Nurse 744 (27%) 240 (31%) 504 (32%)
Physician 1797 (67%) 808 (72%) 989 (62%)
Allied Health 170 (6%) 78 (7%) 92 (6%)
Usual specialty
Anaesthesia 430 (16%) 171 (15%) 259 (16%)
Intensive Care 2019 (74%) 833 (74%) 1186 (75%)
Emergency 72 (3%) 40 (4%) 32 (2%)
Other 190 (7%) 82 (7%) 108 (7%)
Continent
Africa 66 (2%) 44 (4%) 22 (1%)
Asia 437 (16%) 263 (23%) 174 (11%)
Europe 1666 (61%) 470 (42%) 1196 (75%)
North America 224 (8%) 105 (9%) 119 (8%)
Oceania 229 (8%) 194 (17%) 35 (2%)
South America 89 (3%) 50 (4%) 39 (2%)
Hospital type
Community/urban 741 (27%) 268 (24%) 472 (30%)
Tertiary 1548 (57%) 657 (58%) 891 (56%)
Private 237 (9%) 123 (11%) 114 (7%)
Remote/regional 186 (7%) 78 (7%) 108 (7%)
Running capacity
Well above 690 (26%) 141 (13%) 549 (35%)
Above 586 (22%) 169 (15%) 417 (26%)
Below 663 (25%) 400 (36%) 263 (17%)
Unsure 57 (2%) 29 (3%) 28 (2%)
Usual 699 (26%) 375 (34%) 324 (20%)
Data in n (%) for categorical variables andmedianswith interquartile ranges (IQR) for con-
tinuous variables. Type of ICU denotes today's place of work, Mixed ICU includes any ICU
that treats patients with or without COVID-19, as opposed to COVID-19 dedicated or
repurposed ICU that only treats patients with COVID-19. PPE shift duration denotes the
duration the HCW remains dressed in PPE before being able to take a break.
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In the routine care of patients with COVID-19 most respondents re-
ported use of FFP2/N95masks (1557; 58%), Surgicalmaskswere report-
edly used for routine care in 289 (15%) cases but infrequently (47, 2%)
for intubations. Waterproof long sleeve gowns (1623; 67%), and face
shields/visor (1574; 62%). Use of PAPR was infrequent with routine
care (184; 7%) or intubation (254, 13%). Their use was more frequent
in Asian and North American countries compared with Oceania and
Europe but was not associated with the type of ICU, it's capacity or cur-
rent workload. Variations between countries were wide and shown in
the electronic supplementary Tables 3.
A comparison of PPE usage between professions is shown in the
electronic supplementary Table 2. Comparisons should be interpreted
with caution as due to the nature of the survey it is unknown if differ-
ences between respondentsmay is due to their institution or profession.
A comparison of the PPE used in routine care and for intubation
among the respondents is shown in Fig. 1. Six hundred and twenty-
eight (23%) subjects reported use of different mask for intubation com-
pared to routine care. The corresponding numbers for gown and eye
protection are 284 (12%) and 495 (20%). (Table 2).
3.3. PPE availability
More than half of respondents (1402, 52%) reported at least one
piece of the standard PPE as not available, and 817 (30%) reportedthat at least a piece of single-use PPE was being reused or washed as a
result of shortages (Table 2). The distribution of PPE thatwas reportedly
not available or being reused is shown in Table 2. Overall few respon-
dents indicated that no additional PPE should be provided. Among the
1184 (44%) respondents that detailed additional need, this was most
commonly Hazmat suits and PAPRs. Homemade solutions to PPE short-
ages included 3D printed face shields (529, 20%), homemade gowns
(163, 5%), and homemademasks (145, 5%). There were wide variations
between countries, with some reporting up to 19% of some items miss-
ing and others up to 39% being reused (tables electronic supplement 2).
3.4. Knowledge and training
Most of the respondents (2245, 83%) reported that they had formal
training in the use of PPE. That included training at commencement in
the institution (336, 13%) and within the last 2 months due to the
COVID-19 pandemic (1509, 60%). Most reported they would benefit
from additional training, this included simulation (1224, 49%) or dem-
onstration by infection control specialists (478, 19%), and didactic
teaching (220, 9%). Less than half reported having formalized mask fit
testing at any time (1243, 49%). A two-person techniquewas reportedly
used for donning (193, 8%), doffing (159, 6%), or both (643, 26%), some-
times (881, 35%) but never in almost one-quarter (639, 25%) of respon-
dents. Therewas a strong association between reporting never use of a 2
persons technique and never receiving PPE training, fit testing, and low
confidence in using recommended PPE (p < .001 for all comparisons).
3.5. Confidence
Almost half (1211, 45%) reported being very or confident with their
technique in using the available PPE and 138 (5%) were not confident at
all. Confidence in the adequacy of protection was reported by 1187
(44%), while 376 (14%) were not confident at all. This was similar for
doctors, nurses and allied health (p= .93). There was a strong associa-
tion between confidence in protection and the absence of PPE shortage
and confidence in technique (p < .001 for both comparisons).
3.6. Adverse effects
Themedian duration of a shift while wearing PPEwithout the ability
to take a break (PPE-Shift) as 4 h (IQR 2, 5 h). This was similar for nurses
(median 4, IQR 2, 6 h) and doctors (median 4, IQR 3,5 h).
Adverse effects were reported by 80%, including heat (1266, 51%),
thirst (1174, 47%), pressure areas (1088, 44%), headaches (696, 28%), in-
ability to use the bathroom (661, 27%) and extreme exhaustion (4924,
20%) (Table 3). They were all associated with longer duration of shifts
wearing PPE (Table 4).
4. Discussion
This survey provides a snapshot of the reported availability, per-
ceived adequacy of training and provided protection, adverse effects
and usage of PPE among HCW managing COVID-19 patients in critical
care environments from across the globe. It is important to note that
these responses are likely influenced by how burdened HCW are, the
safety culture, and the baseline resources in their institutions. While
these data do not prove adequacy or inadequacy of PPE per se, they do
lend important insights into what HCW are experiencing in this novel
pandemic situation.
It is important to recognize that information on human-to-human
COVID-19 transmission is still emerging. While respiratory droplets
are considered as themain route of transmission, airborne transmission
resulting from aerosol-generating procedures likely is a mode [15]. Sur-
face contamination with transmission using contact means is another
route of infection transfer [16].
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Fig. 1. PPE used for routine care and intubation. PPE used by HCWs for routine care (black bars), and if anything, what additional PPE is used for intubation of COVID-19 patients in an ICU.
Table 2
Shortages and Reuse of single use PPE.
Used for routine
care
Reported as
Missing
Washed or
reused
Mask (n = 2679/2711)*
Surgical Mask 289, (11%) 11, (4%) 13, (4%)
N95/FFP2 maks 1557, (57%) 127, (8%) 267, (17%)
FFP3 mask 649, (24%) 78, (12%) 107, (16%)
PAPR 184, (7%) 16, (9%) n/a
None reported 32 (1%)
Gown (n = 2432/2711)*
Sleeveless apron 193, (7%) 3, (2%) 5, (3%)
Full sleeve waterproof gown 1623, (60%) 115, (7%) 183, (11%)
Hazmat suit 616, (23%) 73, (12%) 66, (11%)
None reported 279 (10%)
Eye Protection (n = 2519/2711)*
Goggles 945, (35%) 28, (3%) 326, (34%)
Face shield or visor 1574, (58%) 131, (8%) 820, (52%)
None reported 192, (7%)
Head protection (n = 2075/2711)*
Hair cover 1636, (60%) 43, (3%) 41, (3%)
Balaclava 317, (12%) 26, (8%) 8, (3%)
Impervious hood 122, (4%) 5, (4%) 11, (9%)
PAPR 184 (7%)
None reported 452, (17%)
Data are expressed in n(%). Denotes number of valid responses for PPE used for routine
care. Reported as missing denoted PPE that would normally be used but is not available.
None reported denotes respondents that did not report using any equipment in that cat-
egory of PPE. Washed or reused denotes single use PPE that is washed or reused due to
stock or availability issues. PAPR shown as Mask and Head protection as includes a hood
and shown as n/a for reuse as they are reusable by design.
* Respondents who reported using a piece of equipment in that category of PPE
Table 3
Adverse effects according to PPE-Shift duration.
PPE-Shift duration: <3 h
n = 727
3–5.9 h
n = 1097
6–8.9 h
n = 524
>9 h
n = 128
Any adverse effects 445, (69%) 815, (86%) 369, (87%) 86, (83%)
Extreme exhaustion 77, (12%) 187, (20%) 116, (27%) 32, (31%)
Inability to use the bathroom 61, (9%) 261, (28%) 176, (41%) 47, (45%)
Headaches 118, (18%) 297, (31%) 137, (32%) 36, (35%)
Thirst 216, (33%) 525, (55%) 213, (50%) 63, (61%)
Heat 290, (45%) 524, (55%) 230, (54%) 56, (54%)
Pressure areas 237, (37%) 495, (52%) 193, (45%) 42, (40%)
Other 17, (3%) 14, (1%) 11, (3%) 2, (2%)
PPE-Shift duration denotes the amount of time inhours that theHCWiswearingPPEwith-
out the ability to take a break. Data expressed in n(%).
Table 4
Effect of PPE-clad shift duration on adverse effects experienced by HCW.
Adverse effect OR (per 1-h shift
duration)
Lower 95%
CI
Upper 95%
CI
p
Any 1.24 1.18 1.30 <0.001
Extreme exhaustion 1.15 1.11 1.20 <0.001
Inability to use bathroom 1.27 1.22 1.31 <0.001
Headaches 1.13 1.09 1.17 <0.001
Thirst 1.16 1.12 1.20 <0.001
Heat 1.07 1.04 1.10 <0.001
Pressure areas 1.06 1.02 1.09 0.001
Univariate logistic regression of duration of PPE-clad shift on adverse effects experienced
by HCWs. The odds ratio represents the change in odds of having the adverse effect with
every 1-h increase in PPE-clad shift duration.
73A. Tabah et al. / Journal of Critical Care 59 (2020) 70–75Recommendations for PPE vary significantly both between and
within countries. As an example, airborne precautions are recom-
mended only for high-risk procedures in some countries whereas this
is routinely in others [6,10,11,17]. Furthermore, shortages of PPE equip-
ment has led to practices to reduce, reuse, or substitute lesser or non-
approved products in an attempt to address inadequate supply of PPE
[18].
Variability in knowledge, training and technique, such as the formal
fit testing of respirators or the use of a 2 persons technique for donningand doffing PPE are correlated with confidence and likely impact safety
of HCWs managing ICU patients infected with COVID-19. These factors
contribute to a sense of uncertainty and lack of confidence in a safe
workplace among HCW [9,19].
Access to appropriate PPE was the first of 8 sources of anxiety in a
group of HCWs interviewing during the first week of the pandemic
[20]. This is likely further exacerbated by frequent changes in guidelines
and public healthmessages. Thosemay be secondary to epidemiological
changes, the rapidly accumulating knowledge but also by the scarcity of
the resource, further increasing anxiety and distrust from HCWs.
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represents a major issue from a supply chain perspective. This further
raises serious concerns about equity and justice related to provision
for those most in need. At local levels, reports of PPE being stolen from
healthcare institutions, misappropriated, or hoarded have occurred
such that this equipment may not be available to those at highest risk
[18]. At subnational and national levels this has also become a concern
as bidding wars and re-direction of orders has occurred. Recent exam-
ples of countries threatening to block export shipments of PPE to
other countries has further exacerbated concerns by HCW around ac-
cess to appropriate PPE. While it is likely that innovative approaches
and ramp-up of domestic manufacturing processes may help to meet
demand, it is a serious risk for low income countries who may ulti-
mately suffer the greatest adverse effects of lack of PPE.
Confirming social media and widely distributed photos of HCWs
bruised faces, most respondents have reported adverse effects from
PPE. This question the safety of currently available PPE when it is worn
for an extended duration. Most of the available PPE was designed and
manufactured for single-use and brief duration of use. These findings
call for urgent design and manufacture of PPE that can be safely worn
and remains effective for extended durations. It also reinforces the
need for recruitment of an increased health care workforce. This would
allow for surge capacity whilst minimizing harm to frontline staff.
There are some limitations of this study that must be noted. First, it is
a voluntary survey and responses reflect opinions and perceptions alone.
They may not necessarily reflect actual practices as these are not con-
firmed through audit. Second, we did not use a systematic sampling
strategy but rather made the survey broadly available and accordingly
there is no denominator to establish a response rate. Therefore, our re-
sults may reflect a small portion and potentially biased reflection of the
true opinions of all HCW. By using scientific society mailing lists we
may have skewed the sampling towards the geographical location of
their members. However, we elected to pursue this study approach in
order to obtain a contemporary view. Given the time frame and rapid
changes related to this pandemic, we therefore elected to pursue this
study without subsequent formalized sampling strategy. This allowed
the identification of trends in reported use of PPE rather than real time
data. Third, the study has an over-representation by physicians which
may underestimate the burden of adverse effects caused by PPE. Fourth,
there is an underrepresentation of low- and middle-income countries,
which may have skewed the results. Finally, we only offered the survey
in English, French, Spanish and Italian. This may have been a barrier for
someHCW to participate andmay have resulted in a selection of respon-
dents thatmay be different hadwe included options for other languages.
5. Conclusion
In summary this survey study provides a snapshot of reported PPE
practices availability, and confidence in adequacy to provide protection
amongHCWsat the frontlines of theCOVID-19pandemic. Respondents re-
port widespread shortages and reuse of single-use PPE items. Half of the
respondents had never had fit-testing of masks. Adverse effects from PPE
usage frequently reported andmostly associatedwith PPE-clad shift dura-
tion. Urgent action by healthcare administrators, policymakers, govern-
ments and industry is warranted to address these issues.
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